Tru Niagen vs Elysium Basis: Which NR Supplement Wins?

Tru Niagen and Elysium Basis are the two best-known nicotinamide riboside (NR) supplements, and they're constantly pitched against each other. Both are built on the same core molecule, both have actual human trials behind them — a genuine rarity in this category — and both reliably do the one thing NR is designed to do: raise blood NAD+. So this is a real comparison, not a marketing mirage. But "which one wins" turns almost entirely on two questions the brands would rather you not ask too hard: does the extra ingredient in Basis buy you a proven benefit, and is either product proven to do anything beyond moving a biomarker? Here's the honest answer.

The two products, side by side

Tru Niagen is the consumer brand for Niagen, ChromaDex's patented form of NR. The standard Tru Niagen serving is 300 mg of NR per capsule (some SKUs go to 500 mg). That's it — NR and not much else. For the full trial-by-trial breakdown of this product on its own, see our Tru Niagen review.

Elysium Basis pairs 250 mg of NR with 50 mg of pterostilbene — a polyphenol chemically related to resveratrol — in a two-capsule daily dose. The pitch is that pterostilbene is a "sirtuin-activating" partner that makes the NR work harder. And Basis typically costs roughly twice as much per month as Tru Niagen for a slightly lower NR dose. So before you weigh any evidence, the raw arithmetic already favors Tru Niagen on NR-per-dollar.

Do they both raise NAD+? Yes — and that part is settled

This is the strongest claim either product can make, and it holds for both.

NR is the rare oral NAD+ precursor with replicated human pharmacokinetic data: a foundational 2016 study established that NR is uniquely and orally bioavailable in humans, raising blood NAD+ after dosing ¹, and a 2018 randomized trial confirmed chronic NR is well tolerated and elevates NAD+ in healthy middle-aged and older adults ². Most relevant to Tru Niagen specifically, a 2019 randomized, double-blind, placebo-controlled trial of the NIAGEN ingredient in healthy overweight adults found it raised whole-blood NAD+ by roughly 40–50% and was safe and well tolerated ³.

Basis has its own dedicated human trial too — and this is important, because it's the exact NR-plus-pterostilbene formulation, not a generic stand-in. A 2017 randomized, double-blind, placebo-controlled study of NRPT (the Basis combination) found that repeat dosing raised whole-blood NAD+ by roughly 40% at the recommended dose, sustainably and safely ⁴. A later hospital trial of the same NRPT formulation in patients with acute kidney injury likewise confirmed it increases NAD+ in a clinical population ⁵.

So on the central biochemical promise — this raises your NAD+ — both products are well supported, and neither has a decisive edge. Basis raised NAD+ ~40%; Tru Niagen's ingredient raised it ~40–50%. Those numbers come from different trials with different methods and aren't directly comparable, but the honest read is: they're in the same ballpark, and both clearly work as NAD+ boosters.

The pterostilbene question: does the extra ingredient earn its premium?

This is where the comparison actually gets decided, because it's the only real formulation difference — and it's the one driving Basis's higher price.

Pterostilbene is a resveratrol-like polyphenol with interesting preclinical, antioxidant, and sirtuin-related biology. But here's the uncomfortable fact for the Basis pitch: there is no human trial showing that adding pterostilbene to NR produces a clinical outcome that NR alone does not. The pivotal NRPT study demonstrated that the combination raises NAD+ safely ⁴ — a biomarker result — not that the pterostilbene component delivers better energy, cognition, longevity, or any felt benefit than plain NR would. Pterostilbene has not been shown, in a head-to-head human trial against NR alone, to improve any hard endpoint.

That matters because the entire premium you pay for Basis over Tru Niagen is, in evidence terms, buying an ingredient whose marginal benefit over NR-alone is unproven in humans. It's not that pterostilbene is useless or unsafe — it's that the claim "NR + pterostilbene beats NR" rests on mechanism and marketing, not on a controlled outcome trial. For the broader pattern of polyphenol "NAD+ partner" claims outrunning the evidence, see our NAD+ and resveratrol stack analysis.

The part neither brand wants emphasized: NAD+ is a biomarker, not an outcome

Here's the framing that should govern this entire decision, and it applies equally to both products: raising NAD+ is not the same as improving how you feel, perform, or age — and in trial after trial, the biomarker moves while the outcome doesn't.

The clearest cautionary results come from NR's own literature. When NR augmented the aged human muscle NAD+ metabolome, it did not improve muscle bioenergetics or physical performance ⁶ — the fuel gauge rose, the engine output stayed flat. On cognition, a randomized placebo-controlled trial in older adults with mild cognitive impairment raised blood NAD+ about 2.6-fold but left neurocognitive scores unchanged ⁷. And a 2025 systematic review and meta-analysis of NR and NMN on skeletal muscle mass and function found no reliable improvement when results were pooled across trials ⁸.

NR does have one concrete, specific functional win: in the NICE randomized trial in peripheral artery disease, six months of NR produced a small but significant improvement in 6-minute walking distance (about +17.6 m between groups) ⁹. But note what that is — a specific outcome, in a specific patient population, not a general energy-or-longevity boost for healthy buyers. This applies to both Tru Niagen and Basis: neither has been proven, in a randomized trial, to deliver the broad anti-aging, energy, or vitality benefits the category markets. They are NAD+ boosters with reassuring safety records and unproven downstream payoffs. For the wider context, start with our NAD+ therapy evidence pillar and our best NAD+ supplements ranking.

So which one wins?

Put the pieces together honestly:

• •Both reliably raise NAD+. Tru Niagen's ingredient ~40–50% ³; Basis's NRPT formulation ~40% ⁴. Effectively a tie on the one claim that's well proven.
• •Both have reassuring short-term safety in dedicated trials ³⁴. They're dietary supplements, not FDA-approved drugs, so neither is approved to treat any condition.
• •Neither has proven downstream benefits — energy, cognition, strength, or longevity — in healthy users ⁶⁷⁸.
• •Tru Niagen is cheaper, with a higher per-capsule NR dose and the deepest brand-specific research footprint.
• •Basis costs roughly double for a lower NR dose plus pterostilbene — an ingredient with no human evidence that it adds benefit over NR alone.

On the evidence, Tru Niagen is the better value: you get the same well-proven NAD+ increase, the same reassuring safety, more NR per capsule, and you're not paying a premium for an unproven add-on. Basis isn't a bad product — it's a legitimate, trial-backed NR supplement — but the case for its higher price depends on a pterostilbene benefit that human trials haven't demonstrated. If you simply want the most cost-effective, best-documented way to raise your NAD+, Tru Niagen wins. If the question is "which one will make me feel younger or more energetic," the honest answer is that neither is proven to — and that's the most important thing to know before spending on either.

Bottom line

Tru Niagen vs Elysium Basis is, at heart, "NR alone, cheaper" versus "NR plus pterostilbene, pricier." Both raise NAD+ ~40% in dedicated human trials ³⁴, both are well tolerated, and both stop short of any proven hard-outcome benefit — because raising NAD+ is a biomarker change, not a demonstrated health result ⁶⁷. The pterostilbene in Basis carries no human evidence of beating NR alone, so the premium is hard to justify on data. For most evidence-minded buyers, Tru Niagen is the more rational pick — but go in understanding you're buying a reliable NAD+ increase, not a proven anti-aging effect. To see how NR compares with the other major precursor, read NMN vs NR: what the human trials show; to weigh the whole shelf by evidence, see the best NAD+ supplements ranking and the NAD+ rankings hub.